Subsequent Events (Details Textual) - Subsequent Event [Member] $ / shares in Units, € in Millions, $ in Millions |
1 Months Ended | ||||
|---|---|---|---|---|---|
|
Feb. 02, 2018
USD ($)
|
Mar. 31, 2018
USD ($)
$ / shares
shares
|
Mar. 31, 2018
EUR (€)
|
Mar. 21, 2018
$ / shares
shares
|
Mar. 31, 2018
EUR (€)
shares
|
|
| Subsequent Event [Line Items] | |||||
| Warrant Term | 7 years | 7 years | 7 years | ||
| Potential Payments Receivable | $ 5.5 | € 4.5 | |||
| Proceeds from Sale of Productive Assets | $ 2.4 | € 2.0 | |||
| Revenue Recognition, Milestone Method, Description | (i) a 1.0 million milestone payment upon the issuance by the European Medical Authority (EMA) of the MAA and (ii) an aggregate of 2.0 million of milestone payments upon approval of the product reimbursement price in certain key countries, provided that the payments in (i) and (ii) are subject to a 50% reduction if the EMA marketing authorization is not received on or prior to September 30, 2019 and shall not be payable in the event such authorization is not received on or prior to March 31, 2020. Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties. | (i) a 1.0 million milestone payment upon the issuance by the European Medical Authority (EMA) of the MAA and (ii) an aggregate of 2.0 million of milestone payments upon approval of the product reimbursement price in certain key countries, provided that the payments in (i) and (ii) are subject to a 50% reduction if the EMA marketing authorization is not received on or prior to September 30, 2019 and shall not be payable in the event such authorization is not received on or prior to March 31, 2020. Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties. | |||
| Warrant [Member] | |||||
| Subsequent Event [Line Items] | |||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1.20 | $ 1.20 | |||
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 40,000 | 540,000 | 40,000 | ||
| Venture Loan [Member] | |||||
| Subsequent Event [Line Items] | |||||
| Early Repayment of Subordinated Debt | $ 3.0 | ||||
| Long-term Debt | $ 7.0 | ||||
| Molteni Loan [Member] | |||||
| Subsequent Event [Line Items] | |||||
| Long-term Debt | $ 4.0 | ||||
| Conversion of Debt to Equity,Description | In addition, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $1.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $1.20 and repay the $1.6 million balance of Horizons loan amount. | In addition, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $1.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $1.20 and repay the $1.6 million balance of Horizons loan amount. | |||
| Proceeds from Subordinated Short-term Debt | $ 2.4 | ||||